Cargando…

Protease Addiction and Synthetic Lethality in Cancer

The “oncogene addiction” concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term “non-oncogene addiction” has been introduced to define the exacerbated necessity of the normal function of non-mutated genes. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freije, José M. P., Fraile, Julia M., López-Otín, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356009/ https://www.ncbi.nlm.nih.gov/pubmed/22655236 http://dx.doi.org/10.3389/fonc.2011.00025

Ejemplares similares

Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas
por: Fraile, Julia M., et al.
Publicado: (2013)

Paralog-based synthetic lethality: rationales and applications
por: Xin, Yucui, et al.
Publicado: (2023)

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
por: Bray, Chandler, et al.
Publicado: (2023)

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy
por: Arna, Ananna Bhadra, et al.
Publicado: (2023)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

NF-κB in premature aging
por: Osorio, Fernando G., et al.
Publicado: (2012)

Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response
por: Das, Shaoli, et al.
Publicado: (2019)

USP49 deubiquitinase regulates the mitotic spindle checkpoint and prevents aneuploidy
por: Campos-Iglesias, Diana, et al.
Publicado: (2023)

ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies
por: Botrugno, Oronza A., et al.
Publicado: (2019)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

Deubiquitination in cancer stem cells
por: Fraile, Julia M., et al.
Publicado: (2017)

Network-targeting combination therapy of leptomeningeal glioblastoma using multiple synthetic lethal strategies: a case report
por: Castro, Michael P., et al.
Publicado: (2023)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

Lon protease: A key enzyme controlling mitochondrial bioenergetics in cancer
por: Quirós, Pedro M, et al.
Publicado: (2014)

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality
por: Yakovlev, Vasily A., et al.
Publicado: (2023)

The metabolic addiction of cancer stem cells
por: Sahoo, Om Saswat, et al.
Publicado: (2022)

EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality
por: Chen, Tingting, et al.
Publicado: (2020)

Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer
por: Bagnoli, Marina, et al.
Publicado: (2022)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
por: Ebeid, Kareem, et al.
Publicado: (2017)

The deubiquitinase USP54 is overexpressed in colorectal cancer stem cells and promotes intestinal tumorigenesis
por: Fraile, Julia M., et al.
Publicado: (2016)

RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells
por: Hölzen, Lena, et al.
Publicado: (2022)

The Degradome database: mammalian proteases and diseases of proteolysis
por: Quesada, Víctor, et al.
Publicado: (2009)

Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019)

Breast Cancer Predisposition Genes and Synthetic Lethality
por: Neiger, Hannah E., et al.
Publicado: (2021)

Inhibitory effects of human cystatin C on plum pox potyvirus proteases
por: García, Juan Antonio, et al.
Publicado: (1993)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
por: Ni, Rui, et al.
Publicado: (2023)

Synthetic Lethality through the Lens of Medicinal Chemistry
por: Myers, Samuel H., et al.
Publicado: (2020)

An in-silico approach to predict and exploit synthetic lethality in cancer metabolism
por: Apaolaza, Iñigo, et al.
Publicado: (2017)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Synthetic lethal approaches to target cancers with loss of PTEN function
por: Ertay, Ayse, et al.
Publicado: (2023)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

Metformin is synthetically lethal with glucose withdrawal in cancer cells
por: Khurana, Ashwani, et al.
Publicado: (2012)

Synthetic lethality in lung cancer and translation to clinical therapies
por: Leung, Ada W. Y., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q34qu5vpm4tisf5o020qc6v4tn